Marja Sankelo

472 total citations
13 papers, 117 citations indexed

About

Marja Sankelo is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Marja Sankelo has authored 13 papers receiving a total of 117 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 6 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Marja Sankelo's work include Multiple Myeloma Research and Treatments (9 papers), Hematopoietic Stem Cell Transplantation (6 papers) and Neutropenia and Cancer Infections (2 papers). Marja Sankelo is often cited by papers focused on Multiple Myeloma Research and Treatments (9 papers), Hematopoietic Stem Cell Transplantation (6 papers) and Neutropenia and Cancer Infections (2 papers). Marja Sankelo collaborates with scholars based in Finland, Sweden and Denmark. Marja Sankelo's co-authors include Raija Silvennoinen, Pentti Mäntymaa, Marjaana Säily, Ville Varmavuo, Esa Jantunen, Timo Siitonen, Jukka Pelkonen, Tarja Laitinen, Anu Partanen and Maija Halme and has published in prestigious journals such as Blood, Human Mutation and Cancers.

In The Last Decade

Marja Sankelo

13 papers receiving 116 citations

Peers

Countries citing papers authored by Marja Sankelo

Since Specialization

Citations

This map shows the geographic impact of Marja Sankelo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marja Sankelo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marja Sankelo more than expected).

Fields of papers citing papers by Marja Sankelo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marja Sankelo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marja Sankelo. The network helps show where Marja Sankelo may publish in the future.

Co-authorship network of co-authors of Marja Sankelo

This figure shows the co-authorship network connecting the top 25 collaborators of Marja Sankelo. A scholar is included among the top collaborators of Marja Sankelo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marja Sankelo. Marja Sankelo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Deep Immune Profiling of Multiple Myeloma at Diagnosis and under Lenalidomide Maintenance Therapy 2023 ·Cancers ·(unknown), (unknown), Komal Kumar Javarappa, Tiina Öhman, Markku Varjosalo, Marjaana Säily, Pekka Anttila, Marja Sankelo, Anu Partanen, Anne Nihtinen, Caroline A. Heckman, Raija Silvennoinen	2
2	Impact of the number of cryopreserved CD34⁺ cells in the infused blood grafts on hematologic recovery and survival in myeloma patients after autologous stem cell transplantation: Experience from the GOA study 2022 ·Journal of Clinical Apheresis ·Anu Partanen, (unknown), Raija Silvennoinen, (unknown), Marja Pyörälä, Timo Siitonen, (unknown), (unknown), Marja Sankelo, Karri Penttilä, Taru Kuittinen, Pentti Mäntymaa, Jukka Pelkonen, Esa Jantunen, Ville Varmavuo	4
3	Comparison of CD34⁺ cell mobilization, blood graft cellular composition, and post‐transplant outcome in myeloma patients mobilized with filgrastim or pegfilgrastim added to low‐dose cyclophosphamide: A prospective multicenter study 2021 ·Transfusion ·Anu Partanen, (unknown), Raija Silvennoinen, Marja Pyörälä, (unknown), Timo Siitonen, (unknown), Marja Sankelo, (unknown), (unknown), Taru Kuittinen, Jukka Pelkonen, Pentti Mäntymaa, Esa Jantunen, Ville Varmavuo	4
4	Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study 2021 ·Transfusion ·(unknown), Raija Silvennoinen, Anu Partanen, (unknown), Timo Siitonen, (unknown), Marja Sankelo, Marja Pyörälä, Taru Kuittinen, Karri Penttilä, (unknown), Eeva‐Riitta Savolainen, Pentti Mäntymaa, Jukka Pelkonen, Ville Varmavuo, Esa Jantunen	11
5	Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients 2020 ·Blood ·Raija Silvennoinen, Hareth Nahi, Pekka Anttila, Perttu Koskenvesa, (unknown), (unknown), Ville Varmavuo, (unknown), (unknown), Marjaana Säily, Anu Partanen, Marja Sankelo, (unknown), Pentti Mäntymaa, (unknown), (unknown), Lene Kongsgaard Nielsen, Esa Jantunen, Caroline A. Heckman	3
6	Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study 2018 ·Leukemia & lymphoma ·(unknown), Raija Silvennoinen, Antti Ropponen, Timo Siitonen, Marjaana Säily, Marja Sankelo, (unknown), Anu Partanen, Marja Pyörälä, Eeva‐Riitta Savolainen, Pentti Mäntymaa, Jukka Pelkonen, Esa Jantunen, Ville Varmavuo	7
7	Impact of lenalidomide‐based induction therapy on the mobilization of CD34⁺ cells, blood graft cellular composition, and post‐transplant recovery in myeloma patients: a prospective multicenter study 2017 ·Transfusion ·Anu Partanen, (unknown), Raija Silvennoinen, Antti Ropponen, Timo Siitonen, (unknown), Marja Sankelo, Jukka Pelkonen, Pentti Mäntymaa, Ville Varmavuo, Esa Jantunen	9
8	Bloodstream infections in acute myeloid leukemia patients treated according to the Finnish Leukemia Group AML-2003 protocol – a prospective nationwide study 2017 ·Infectious Diseases ·(unknown), Marjatta Sinisalo, Reetta Huttunen, Jaana Syrjänen, Janne Aittoniemi, Heini Huhtala, Marja Sankelo, (unknown), Riikka Räty, Esa Jantunen, Tapio Nousiainen, Marjaana Säily, Marjut Kauppila, Maija Itälä‐Remes, (unknown), Auvo Rauhala, Pirjo Koistinen, Erkki Elonen, (unknown)	26
9	Cost analysis of a randomized stem cell mobilization study in multiple myeloma 2016 ·Annals of Hematology ·Ville Varmavuo, Raija Silvennoinen, Pekka Anttila, Marjaana Säily, Marja Sankelo, (unknown), Jouni Ahonen, Eija Mahlamäki, Pentti Mäntymaa, Eeva‐Riitta Savolainen, Kari Remes, Esa Jantunen	8
10	Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low‐dose cyclophosphamide: a randomized comparison 2016 ·Transfusion ·(unknown), Raija Silvennoinen, Antti Ropponen, Timo Siitonen, Marjaana Säily, Marja Sankelo, (unknown), (unknown), Taru Kuittinen, Jukka Pelkonen, Pentti Mäntymaa, Kari Remes, Ville Varmavuo, Esa Jantunen	11
11	Accurate genetic diagnosis of Finnish pulmonary arterial hypertension patients using oligonucleotide‐selective sequencing 2015 ·Molecular Genetics & Genomic Medicine ·(unknown), (unknown), Pertteli Salmenperä, (unknown), Jonna Tallila, Massimiliano Gentile, Marja Sankelo, Tarja Laitinen, Juha Koskenvuo, Tero‐Pekka Alastalo, Samuel Myllykangas	5
12	Hereditary hemorrhagic telangiectasia type 1 and 2 mutations in Finland 2008 ·Acta Oto-Laryngologica ·Marja Sankelo, Maija Halme, Tarja Laitinen, Petri S. Mattila	2
13	BMPR2 mutations have short lifetime expectancy in primary pulmonary hypertension 2005 ·Human Mutation ·Marja Sankelo, (unknown), Rajiv D. Machado, Rachel Harrison, Nung Rudarakanchana, Nicholas W. Morrell, (unknown), Maija Halme, Hannu Puolijoki, Juha Kere, Outi Elomaa, Markku Kupari, Anne Räisänen‐Sokolowski, Richard C. Trembath, Tarja Laitinen	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact